Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dTACE-HAIC is a combination treatment protocol developed by the Second Affiliated Hospital of Guangzhou Medical University for the treatment of unresectable large hepatocellular carcinoma (>7cm). The protocol integrates Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) using pirarubicin-loaded CalliSpheres with Hepatic Arterial Infusion Chemotherapy (HAIC) using the FOLFOX regimen (oxaliplatin, 5-fluorouracil, and leucovorin). This dual approach combines the embolization-induced ischemia and localized high-concentration chemotherapy of DEB-TACE with the continuous regional infusion of HAIC to maximize anti-tumor efficacy. The treatment is currently being evaluated in a Phase 3 clinical trial to compare its effectiveness and safety against HAIC alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dTACE-HAIC.